Sotagliflozin
Sotagliflozin, sold under the brand name Zynquista, is a drug approved in the European Union for people with type 1 diabetes.[2][1]
 | |
| Clinical data | |
|---|---|
| Trade names | Zynquista |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.231.837  |
| Chemical and physical data | |
| Formula | C21H25ClO5S |
| Molar mass | 424.94 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The most common side effect is genital infection in women.[1] Other common side effects include diabetic ketoacidosis, diarrhoea and genital infection in men.[1]
The US Food and Drug Administration (FDA) refused its approval for use in combination with insulin for the treatment of type 1 diabetes. It is developed by Lexicon Pharmaceuticals.[3][4][5]
Sotagliflozin is a combination sodium/glucose cotransporter 1 and 2 (SGLT1/2) inhibitor and is in the class of drugs known as gliflozins.
References
- "Zynquista EPAR". European Medicines Agency (EMA). 27 February 2019. Retrieved 28 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- Zynquista approved in EU for certain patients with type I diabetes
- "Sotagliflozin as an Adjunct to Insulin for Type 1 Diabetes" (PDF). U.S. Food and Drug Administration (FDA).
- "Sanofi: FDA advisory committee votes on Zynquista (sotagliflozin) as treatment for adults with type 1 diabetes" (Press release). Sanofi. 17 January 2019 – via GlobeNewswire.
- "Sanofi: FDA advisory committee votes on Zynquista (sotagliflozin) as treatment for adults with type 1 diabetes". Sanofi (Press release). 18 January 2019. Retrieved 28 October 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.